Evidence map›Paper›PMID 36777690›Full record

ArticleLancet regional health. Americas2022

Overdose deaths involving non-BZD hypnotic/sedatives in the USA: Trends analyses.

Vitor S Tardelli, Marina C M Bianco, Rashmika Prakash, Luis E Segura, João M Castaldelli-Maia, Thiago M Fidalgo, Silvia S Martins

Abstract read
In one paragraph

Article in Lancet regional health. Americas, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Balancing Risk and Uncertain Benefit in Pharmacotherapy for Pain in Kidney Transplant Recipients.Clinical journal of the American Society of Nephrology : CJASN · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vitor S TardelliDepartamento de Psiquiatria, Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brazil.
Marina C M BiancoDepartamento de Psiquiatria, Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brazil.
Rashmika PrakashDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.
Luis E SeguraDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.
João M Castaldelli-MaiaDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.
Thiago M FidalgoDepartamento de Psiquiatria, Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brazil.
Silvia S MartinsDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There is sparse knowledge on overdose deaths resulting from non-benzodiazepines and gabapentinoids usage. We examined overdose death rate across demographics categories and the overdose death trends over time. Methods: Using data from the National Center for Health Statistics (USA), we identified 21,167 persons that died with an overdose ICD code as the underlying cause of death and had a T42.6/T42.7 ICD code, which include gabapentinoids and z-drugs, among their multiple causes of death. The overdose death rate was calculated per 100,000 persons for every year between 2000 and 2018. We used joinpoint regression analyses to assess trends over time. Results: We identified a rise in the proportion of deaths with a T42.6/T42.7 ICD code between 2000 and 2006 (yearly change: +0.06) and between 2006 and 2015 (yearly change: +0.32). From 2000 to 2008, the proportion of deaths with any other T code rose significantly (yearly change: +3.56). Between 2008 and 2018, there was also a significant rise (yearly change: +1.31). From 2000 to 2015, the proportion of deaths with a T42.6/T42.7 ICD code with any other T code rose (yearly change: +2.58). From 2000 to 2015, the proportion of deaths with a T42.6/T42.7 ICD code with a concurrent benzodiazepine T code rose (yearly change: +1.98). From 2000 to 2005, the proportion of alcohol T codes rose non-significantly (yearly change: +0.35). Finally, the proportion of alcohol T codes fell significantly between 2008 and 2018 (yearly change: - 0.74). Interpretation: Deaths due to non-benzodiazepine hypnotics and gabapentinoids increased significantly over the last two decades. Clinicians should not assume that replacing benzodiazepines and opioids with these medications necessarily lowers risk to the patient. Funding: This study was funded by an internal grant from the Columbia University President's Global Innovation Fund (PI: Martins).

Identifiers

PMID36777690
PMCPMC9904096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.